MetaVia Inc.
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed… Read more
MetaVia Inc. (MTVA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.467x
Based on the latest financial reports, MetaVia Inc. (MTVA) has a cash flow conversion efficiency ratio of -0.467x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.96 Million) by net assets ($6.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
MetaVia Inc. - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how MetaVia Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
MetaVia Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MetaVia Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EQUIFAX INC - Dusseldorf Stock Exchang
DU:EFX
|
0.095x |
|
ATI Physical Therapy Inc
NYSE:ATIP
|
-0.071x |
|
INSMED
BE:IM8N
|
-0.374x |
|
CTT Pharmaceutical Holdings Inc
PINK:CTTH
|
-0.200x |
|
Lord Resources Ltd
AU:LRD
|
-0.317x |
|
Oscar Properties Holding AB
ST:OP
|
0.151x |
|
Forbidden Foods Ltd
AU:FFF
|
-0.112x |
|
Kancera AB (publ)
ST:KAN
|
-0.227x |
Annual Cash Flow Conversion Efficiency for MetaVia Inc. (2014–2024)
The table below shows the annual cash flow conversion efficiency of MetaVia Inc. from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.93 Million | $-24.71 Million | -3.116x | -381.38% |
| 2023-12-31 | $16.68 Million | $-10.80 Million | -0.647x | -20.19% |
| 2022-12-31 | $21.75 Million | $-11.71 Million | -0.538x | +48.06% |
| 2021-12-31 | $14.60 Million | $-15.13 Million | -1.037x | +30.62% |
| 2020-12-31 | $7.20 Million | $-10.76 Million | -1.494x | -160.96% |
| 2019-12-31 | $12.29 Million | $-7.04 Million | -0.573x | -152.65% |
| 2018-12-31 | $-13.29 Million | $-14.45 Million | 1.088x | +115.93% |
| 2017-12-31 | $3.94 Million | $-26.90 Million | -6.826x | -1175.31% |
| 2016-12-31 | $20.63 Million | $-11.04 Million | -0.535x | -221.96% |
| 2015-12-31 | $-12.38 Million | $-5.43 Million | 0.439x | +19.50% |
| 2014-12-31 | $-531.00K | $-195.00K | 0.367x | -- |